Clinical trials: IgA Nephropathy
IgA Nephropathy, Glomerular Diseases
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with…
- Trial name
- INTEREST (NCT02954419)
- Testing
- No intervention
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Sun Yat-sen University
Chronic Kidney Disease
Effect of Statins on IgG, IgA and IgM Level in Chronic Hemodialysis Patients
This is double blind randomized controlled trial on the statins effects on serum IgG, IgA and IgM level in chronic hemodialysis patients in Bandarabbas
- Trial name
- NCT01305317
- Testing
- Lipitor
- Where
- Iran
- Volunteers
- 74 people
- Sponsor
- Hormozgan University of Medical Sciences
IgA Nephropathy
Correlation of Microbiome and Metabonomics With IgA Nephropathy
IgAN is the most prevalent primary glomerulonephritis in China, is characterized by the deposition of IgA1 (particularly, galactose-deficient IgA1) in the glomerular mesangium.
- Trial name
- NCT05190848
- Where
- 5 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital
IGA Glomerulonephritis
Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis
OBJECTIVES: I. Determine whether allelic differences associated with the fourth component of complement, type-1 complement receptor expressed on erythrocytes, and Fc receptor FcgRIII contribute to the pathogenesis of IgA…
- Trial name
- NCT00004305
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Center for Research Resources (NCRR)
Glomerular Disease, Minimal Change Disease
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Glomerulonephritis (GN) generates an enormous individual and social economic burden. However, the therapeutic options are largely based on clinical and pathological parameters and the individual response to therapy or prognosis…
- Conditions
- Glomerular Disease, Minimal Change Disease, IgA Nephropathy, Membranous Nephropathy
- Trial name
- KORNERSTONE (NCT03929887)
- Testing
- Kidney Biopsy
- Where
- 6 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Seoul National University Hospital
IgA Nephropathy
The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients
The study is to evaluate the effect of Mycophenolate Mofetil compared with losartan alone on time to doubling of serum creatinine or the onset of end stage renal disease in patients with advanced IgA nephropathy who are treated…
- Trial name
- MAIN (NCT01854814)
- Testing
- Mycophenolate mofetil, Losartan
- Where
- 3 sites in China
- Volunteers
- 238 people
- Sponsor
- Fan Fan Hou
Glomerulonephritis, IGA
ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT
IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN.
- Trial name
- NCT00378443
- Testing
- prednisone + Inhibace/Cozaar, Inhibace/Cozaar
- Sponsor
- Peking University
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
IgA Nephropathy, Lupus Nephritis (LN)
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older with Immunoglobulin A Nephropathy…
- Conditions
- IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
- Trial name
- NCT06419205
- Testing
- ADX-097
- Where
- 4 sites in United States, Brazil
- Volunteers
- 30 people
- Sponsor
- Akebia Therapeutics
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219CX.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07586267
- Testing
- QT-219CX
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
IgA Glomerulonephritis
Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy
OBJECTIVES: Evaluate the efficacy of alternate day prednisone versus daily fish oil supplements in slowing or preventing the decline in renal function in children, adolescents, and young adults with moderate to severe…
- Trial name
- NCT00004448
- Testing
- omega-3 fatty acids, prednisone
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary Immunoglobulin A Nephropathy (IgAN)
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (including CV surveillance) of iptacopan in primary immunoglobulin A…
- Trial name
- NCT06994845
- Testing
- iptacopan
- Where
- 20 sites in United States, Argentina and 6 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy, Glomerular Diseases
Biomarkers for the Progression of IgA Nephropathy
IgA nephropathy (IgAN) is the most prevalent primary glomerular disease worldwide and an important cause of end stage renal disease.
- Trial name
- NCT02529722
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Istanbul University
Glomerulonephritis, IGA
Efficacy and Safety of Losartan in Children With Ig A Nephropathy
The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.
- Trial name
- NCT02232776
- Testing
- Losartan
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Seoul National University Hospital
IgA Nephropathy
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
A multi-center, randomized, controlled clinical trial to evaluate the short-term and long-term efficacy and safety of mycophenolate mofetil (MMF) in reducing proteinuria and preserving renal function in patients with IgAN who…
- Trial name
- NCT00657059
- Testing
- irbesartan, methylprednisolone (MP) or prednisone (pred), mycophenolate mofetil (MMF)
- Where
- China
- Volunteers
- 151 people
- Sponsor
- Sun Yat-sen University
IgA Nephropathy
Steroids Therapy in IgA Nephropathy With Crescents
This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of steroids therapy for patients of IgA nephropathy with crescents.
- Trial name
- NCT04833374
- Testing
- Methylprednisolone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
IgA Nephropathy
A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy
This is a survey of factors which affect a pathologically defined early or delayed diagnosis of IgA nephropathy in Guangdong General Hospital, Guangzhou, China.
- Trial name
- NCT01538433
- Where
- China
- Volunteers
- 603 people
- Sponsor
- Guangdong Provincial People's Hospital
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.
IGA Nephropathy
"Steroids and Azathioprine Versus Steroids Alone in IgAN"
In a previous trial the investigators found that the effect of steroids in IgA nephropathy diminish over time. The difference in renal survival is striking up till the third year, but then remains constant.
- Trial name
- NCT00755859
- Testing
- steroids plus azathioprine, steroids
- Where
- 28 sites in Italy, Switzerland
- Volunteers
- 206 people
- Sponsor
- A. Manzoni Hospital
IgA Nephropathy
Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.
The purpose of this study is to determine whether Multi-glycoside of Tripterygium Wilfordii HOOK. f. is effective and safe in the treatment of IgA nephropathy.
- Trial name
- NCT02187900
- Testing
- Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH), Mycophenolate mofetil (MMF)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Second Xiangya Hospital of Central South University